On June 12, the Zhejiang Provincial Food and Drug Administration issued the first phase of the 2020 Zhejiang Province Drug Quality Inspection and Announcement (hereinafter referred to as "announcement").
The announcement pointed out that the bureau has recently organized and carried out random sampling inspections of the relevant drug quality of the drug production, operation and use units within its jurisdiction. During the inspection, it was found that 48 batches of drugs did not comply with the regulations.
Among them, 8 batches are preparations and 40 batches are decoction pieces. Among the 48 batches of drugs, Kudiezi injection produced by Shenyang Shuangding Pharmaceutical Co., Ltd. and Fabanxia produced by Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd. all had re-inspection results in compliance with the regulations. This also means that the product quality problem is not a production quality problem of the production enterprise, and the quality problem may appear in other links such as circulation, transportation or storage.
In addition, it should be noted that there are many commonly used drugs in these 48 batches of drugs, including Yupingfeng oral liquid, Niuhuang Jiedu tablets, antiviral oral liquid, compound paracetamol tablets, Guizhi Fuling pills, Banlangen, honeysuckle...
For the above unqualified drugs, the bureau requires that, based on the measures that have been taken, all localities should further check and dispose of drugs and related units that do not meet the standards, effectively eliminate hidden dangers, and ensure the quality and safety of drugs.
